Short interest in Mainz Biomed NV (NASDAQ:MYNZ) decreased during the last reporting period, falling from 1.70M to 1.52M. This put 8.25% of the company's publicly available shares short.

NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to ...

In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with ...

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Mainz Biomed announced a 1-for-40 reverse stock split to maintain its Nasdaq listing, aiming to boost its ...

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.